Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 21, Issue 1, Pages 3-5Publisher
NATURE PORTFOLIO
DOI: 10.1038/d41573-021-00202-8
Keywords
-
Ask authors/readers for more resources
The FDA is considering authorizations for Pfizer's paxlovid and Merck & Co.'s molnupiravir, the first two oral COVID-19 antivirals.
The FDA is considering authorizations for Pfizer's paxlovid and Merck & Co.'s molnupiravir, the first two oral COVID-19 antivirals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
